JNJ - J&J FDA close to deal allowing release of vaccine from troubled Emergent plant - WSJ

The FDA and Johnson & Johnson (JNJ) are close to an announcement that millions of its doses produced at a troubled Baltimore Emergent BioSolutions (EBS) can be released, according to The Wall Street Journal.The vaccines can be distributed because contamination issues, detailed in an FDA inspection, have been corrected.Emergent made headlines back in March after it was reported 15M J&J vaccine doses were contaminated due to human error.The newspaper reports that regulators and J&J have tentatively agreed that ~60M vaccine doses will be made available for the U.S. and abroad.The Journal also said that about 60M AstraZeneca (AZN) vaccine doses, manufactured at the same plant, could be made available in the coming weeks as part of a separate agreement with the FDA.J&J shares are up 0.1% to $169.05, Emergent shares are up 5.5% to $61, and AstraZeneca shares are up a penny to $56.90 in after-hours trading.

For further details see:

J&J, FDA close to deal allowing release of vaccine from troubled Emergent plant - WSJ